MedTrace Logo

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

NCT00303017 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-10-21

No results posted yet for this study

Summary

safety, efficacy and acceptability of Flavocoxid

Conditions

Interventions

DIETARY_SUPPLEMENT

flavocoxid

flavonoid mixture

DRUG

Naproxen

non-steroidal anti-inflammatory drug

Sponsors & Collaborators

  • Primus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joy Schechtman, DO · Sun Valley Arthritis Ltd, 6525 W. Sack Drive Suite 108 Glendale AZ 85308 Phone 623-825-5591 Fax 623

  • Timothy Truitt, MD · MIMA Century Research Associates 65 E. Nasa Blvd. Suite 106 Melbourne FL 32901 Phone 321 723-1203 Fax 321-725-3602

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-07-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00303017 on ClinicalTrials.gov